Vertex Pharmaceuticals Shares Drop 2.97% to $347.74 on Difficult Trading Day

August 11, 2023

Categories: BiotechnologyTags: , , Views: 29

🌧️Trending News

Vertex Pharmaceuticals ($NASDAQ:VRTX) Inc. (VRTX) experienced a difficult trading day on Thursday, as their shares dropped by 2.97% to $347.74. This was in line with the overall performance of the stock market, which saw a sharp decline during the day. Vertex Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts. The company specializes in the research, development, and commercialization of innovative drugs for the treatment of serious diseases across a range of therapeutic areas, including cystic fibrosis, hereditary angioedema, and viral infections. The company’s products are supported by a strong pipeline of potential new medicines.

In addition, Vertex has established collaborations with various organizations in order to develop treatments for genetic disorders and other diseases. Vertex’s stock price is highly sensitive to news about its clinical trials, FDA decisions and other developments in the areas of medicine that the company is working on. As such, these events can often have a significant impact on share prices. For this reason, investors should always be aware of the latest news and developments at Vertex Pharmaceuticals Inc. when considering investing in their stock.


At GoodWhale, we recently conducted an analysis of VERTEX PHARMACEUTICALS‘ wellbeing. Our Risk Rating gave VERTEX PHARMACEUTICALS a high risk investment rating for its financial and business aspects. We have identified four risk warnings in VERTEX PHARMACEUTICALS income sheet, balance sheet, cashflow statement, and non-financials. To learn more about our findings on VERTEX PHARMACEUTICALS’ wellbeing, you can register at and view our full report. Through our analysis, we can help investors make informed decisions about their investments in VERTEX PHARMACEUTICALS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Vertex Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    9.51k 3.36k 39.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Vertex Pharmaceuticals. More…

    Operations Investing Financing
    4.07k -321.1 -67.7
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Vertex Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    20.35k 4.88k 56.04
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Vertex Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    20.7% 28.6% 45.8%
    FCF Margin ROE ROA
    40.9% 18.9% 13.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The competition in the pharmaceutical industry is intense, with companies vying for market share in a constantly changing landscape. Vertex Pharmaceuticals Inc is no stranger to this competition, and its competitors include Nyrada Inc, Incyte Corp, and Gain Therapeutics Inc.

    – Nyrada Inc ($ASX:NYR)

    Nyrada Inc is a clinical stage biopharmaceutical company focused on the development of novel therapeutics to treat diseases of the eye, central nervous system and other organ systems. The company’s lead product candidate, NYX-2925, is a small molecule that inhibits the activity of the protein kinase C-beta (PKC-beta) enzyme. NYX-2925 is in clinical development for the treatment of dry eye disease and age-related macular degeneration.

    Nyrada’s market cap is $21.06 million and its ROE is -20.85%. The company is focused on the development of novel therapeutics to treat diseases of the eye, central nervous system and other organ systems.

    – Incyte Corp ($NASDAQ:INCY)

    Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, primarily in oncology.

    As of 2022, Incyte Corporation had a market capitalization of $15.48 billion and a return on equity of 9.54%. The company’s main product is Jakafi (ruxolitinib), which is approved for the treatment of myelofibrosis and polycythemia vera, two rare blood disorders. Incyte is also developing several other drugs in clinical trials for various cancers.

    – Gain Therapeutics Inc ($NASDAQ:GANX)

    Gain Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with serious diseases. The company’s lead product candidate is GT-004, a small molecule inhibitor of the oncogene c-Myc, which is in development for the treatment of solid tumors. Gain Therapeutics has a market cap of $36.13 million and a negative return on equity of 33.26%. The company’s products are still in development and have not yet been approved for sale by the FDA.


    Vertex Pharmaceuticals Inc. saw a 2.97% decline in share price to $347.74 on Thursday, a sign of the bearish sentiment seen in the broader markets. Analysts suggest that investors should research the company’s financials and fundamentals to determine if it is a long-term investment opportunity. Specifically, they should look at the company’s competitive advantage in the industry, its debt-to-equity ratio, operating margins, revenue growth, and return on investment. With these metrics in mind, investors can make a more informed decision about whether Vertex Pharmaceuticals is a good buy.

    Recent Posts

    Leave a Comment